Enantioselective Pharmacokinetics of Venlafaxine in the Presence of CYP2D6 Inhibition: A Population Parent–Metabolite Modeling Approach

Documenti analoghi

• CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression
  di: Xiaoyu Men, et al.
  Pubblicazione: (2024)
• Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects
  di: Martha Gonzalez, et al.
  Pubblicazione: (2025)
• Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions of Soticlestat as a Victim of CYP Induction and Inhibition, and as a Perpetrator of CYP and P–Glycoprotein Inhibition
  di: Hongxia Jia, et al.
  Pubblicazione: (2025)
• Mechanistic Framework to Predict Maternal‐Placental‐Fetal Pharmacokinetics of Nifedipine Employing Physiologically Based Pharmacokinetic Modeling Approach
  di: Marya Antônya Werdan Romão, et al.
  Pubblicazione: (2024)
• Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib
  di: Panli Cardona, et al.
  Pubblicazione: (2024)